Clonidine Treatment for Neonatal Abstinence Syndrome

可乐定治疗新生儿戒断综合症

基本信息

  • 批准号:
    7013237
  • 负责人:
  • 金额:
    $ 12.21万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2003
  • 资助国家:
    美国
  • 起止时间:
    2003-09-30 至 2008-01-31
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): In the United States, as many as 20,000 babies a year are born to opioid ("narcotic") addicted mothers. Like their mothers, these infants are opioid dependent. Following birth, the infant is removed from its opioid source, inducing a withdrawal syndrome in these infants. Withdrawal symptoms in newborns include vomiting, diarrhea, poor feeding, tachycardia, hypertension, diaphoresis, restlessness, insomnia, irritability, tremors, clonus, hyperphagia with poor growth and acidosis, reversible neurologic abnormalities, and even seizures. This complex of signs and symptoms is referred to as neonatal abstinence syndrome (NAS). Reinstitution of opioids followed by a slow tapering protocol is currently the standard of care, necessitating prolonged hospitalization from weeks to months. Clonidine is a non-narcotic central alpha2-adrenergic receptor agonist that blocks the effects of over-excitation of the sympathetic nervous system and is an approved treatment for opioid withdrawal in adults. We currently have a physician sponsored IND (#63,781) to study the effect of clonidine as adjunct therapy to opioids for the treatment of NAS. This proposal will test the hypothesis that combination therapy of clonidine and opioids is 1) safe and efficacious, 2) allows reduced amount of opioid drug use, and 3) results in shorter time of treatment and hospitalization. This will be accomplished in a randomized, placebo controlled double blind clinical trial comparing diluted tincture of opium (DTO) combined with a placebo (control) vs. DTO combined with clonidine. Additional sub-studies include determination of 1) pharmacokinetics and pharmacodynamics of DTO and clonidine in the enrolled cohort and 2) further safety evaluation by evaluating developmental outcome on the Bayley Scale of Infant Development (BSID) at 6 and 12 months of age. Pharmacokinetics will be determined by measuring serum concentrations of clonidine and morphine and analyzing volume of distribution, elimination half-life and clearance. These results will have important clinical implications and may change the standards of care not only for management of infants with severe NAS, but also for the management of infants and children, after long-term iatrogenic opioid exposure for instance following prolonged analgesia for mechanical ventilation or multiple operations.
描述(由申请人提供):在美国,每年有多达20,000名婴儿出生在阿片类药物(“麻醉剂”)成瘾的母亲手中。和他们的母亲一样,这些婴儿也依赖阿片类药物。出生后,婴儿被从阿片类药物来源中移除,导致这些婴儿出现戒断综合征。新生儿戒断症状包括呕吐、腹泻、喂养不良、心动过速、高血压、出汗、躁动、失眠、易怒、震颤、耳鸣、生长不良的嗜食和酸中毒、可逆性神经系统异常,甚至癫痫发作。这种复杂的体征和症状被称为新生儿戒断综合征(NAS)。目前的标准治疗方案是重新使用阿片类药物,然后缓慢减量,因此需要延长住院时间,从数周到数月不等。可口定是一种非麻醉性中枢α 2-肾上腺素能受体激动剂,可阻断交感神经系统过度兴奋的作用,是成人阿片类药物戒断的批准治疗药物。我们目前有一个医生赞助的IND(#63,781)来研究可乐定作为阿片类药物治疗NAS的辅助疗法的效果。本提案将验证可乐定和阿片类药物联合治疗的假设:1)安全有效,2)减少阿片类药物的使用,3)缩短治疗和住院时间。这将在一项随机、安慰剂对照的双盲临床试验中完成,该试验比较了稀释的鸦片酊剂(DTO)与安慰剂(对照)和DTO与可乐定的联合。其他子研究包括确定1)DTO和可乐定在入组队列中的药代动力学和药效学,2)通过评估6个月和12个月时Bayley婴儿发育量表(BSID)的发育结果进一步进行安全性评估。药代动力学将通过测定可乐定和吗啡的血清浓度和分析分布量、消除半衰期和清除率来确定。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

ESTELLE B. GAUDA其他文献

ESTELLE B. GAUDA的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('ESTELLE B. GAUDA', 18)}}的其他基金

Efficacy of clonidine in reducing iatrogenic-induced opioid dependence in infants
可乐定减少婴儿医源性阿片类药物依赖的功效
  • 批准号:
    8066685
  • 财政年份:
    2010
  • 资助金额:
    $ 12.21万
  • 项目类别:
Efficacy of clonidine in reducing iatrogenic-induced opioid dependence in infants
可乐定减少婴儿医源性阿片类药物依赖的功效
  • 批准号:
    8272767
  • 财政年份:
    2010
  • 资助金额:
    $ 12.21万
  • 项目类别:
Efficacy of clonidine in reducing iatrogenic-induced opioid dependence in infants
可乐定减少婴儿医源性阿片类药物依赖的功效
  • 批准号:
    7875132
  • 财政年份:
    2010
  • 资助金额:
    $ 12.21万
  • 项目类别:
DUAL ENZYME-BASED MICROBIOSENSOR TO MEASURE ATP RELEASE FROM THE CAROTID BODY
基于双酶的微生物传感器测量颈动脉体的 ATP 释放
  • 批准号:
    7391737
  • 财政年份:
    2007
  • 资助金额:
    $ 12.21万
  • 项目类别:
Immersion in Drug Abuse
沉浸在药物滥用中
  • 批准号:
    7266693
  • 财政年份:
    2007
  • 资助金额:
    $ 12.21万
  • 项目类别:
Immersion in Drug Abuse
沉浸在药物滥用中
  • 批准号:
    7455956
  • 财政年份:
    2007
  • 资助金额:
    $ 12.21万
  • 项目类别:
Immersion in Drug Abuse
沉浸在药物滥用中
  • 批准号:
    8056794
  • 财政年份:
    2007
  • 资助金额:
    $ 12.21万
  • 项目类别:
DUAL ENZYME-BASED MICROBIOSENSOR TO MEASURE ATP RELEASE FROM THE CAROTID BODY
基于双酶的微生物传感器测量颈动脉体的 ATP 释放
  • 批准号:
    7261771
  • 财政年份:
    2007
  • 资助金额:
    $ 12.21万
  • 项目类别:
Immersion in Drug Abuse
沉浸在药物滥用中
  • 批准号:
    7848238
  • 财政年份:
    2007
  • 资助金额:
    $ 12.21万
  • 项目类别:
Immersion in Drug Abuse
沉浸在药物滥用中
  • 批准号:
    7632991
  • 财政年份:
    2007
  • 资助金额:
    $ 12.21万
  • 项目类别:

相似海外基金

The IDeA State Consortium for a Clinical Research Resource Center: Increasing Clinical Trials in IDeA States through Communication of Opportunities, Effective Marketing, and WorkforceDevelopment
IDeA 州临床研究资源中心联盟:通过机会交流、有效营销和劳动力发展增加 IDeA 州的临床试验
  • 批准号:
    10715568
  • 财政年份:
    2023
  • 资助金额:
    $ 12.21万
  • 项目类别:
CAPRISA CASCADE Clinical Trials Network Clinical Research Site
CAPRISA CASCADE 临床试验网络临床研究网站
  • 批准号:
    10754981
  • 财政年份:
    2023
  • 资助金额:
    $ 12.21万
  • 项目类别:
TO PROVIDE BIO-MEDICAL AND BEHAVIORAL RESEARCH RESOURCES AND CLINICAL RESEARCH COORDINATING SERVICES TO SUPPORT THE NIDA CLINICAL TRIALS NETWORK (CTN)
提供生物医学和行为研究资源以及临床研究协调服务以支持 NIDA 临床试验网络 (CTN)
  • 批准号:
    10617997
  • 财政年份:
    2022
  • 资助金额:
    $ 12.21万
  • 项目类别:
TO PROVIDE BIO-MEDICAL AND BEHAVIORAL RESEARCH RESOURCES AND CLINICAL RESEARCH COORDINATING SERVICES TO SUPPORT THE NIDA CLINICAL TRIALS NETWORK (CTN)
提供生物医学和行为研究资源以及临床研究协调服务以支持 NIDA 临床试验网络 (CTN)
  • 批准号:
    10538151
  • 财政年份:
    2021
  • 资助金额:
    $ 12.21万
  • 项目类别:
Health 360x Clinical Research Platform for Scalable Access to Clinical Trials
Health 360x 临床研究平台可扩展临床试验的访问
  • 批准号:
    10624966
  • 财政年份:
    2021
  • 资助金额:
    $ 12.21万
  • 项目类别:
Health 360x Clinical Research Platform for Scalable Access to Clinical Trials
Health 360x 临床研究平台可扩展临床试验的访问
  • 批准号:
    10515803
  • 财政年份:
    2021
  • 资助金额:
    $ 12.21万
  • 项目类别:
Health 360x Clinical Research Platform for Scalable Access to Clinical Trials
Health 360x 临床研究平台可扩展临床试验的访问
  • 批准号:
    10258627
  • 财政年份:
    2021
  • 资助金额:
    $ 12.21万
  • 项目类别:
New Mexico Clinical Trials Node: Clinical research and practice to address substance use in diverse, rural and underserved populations
新墨西哥州临床试验节点:解决多样化、农村和服务不足人群的药物使用问题的临床研究和实践
  • 批准号:
    10581505
  • 财政年份:
    2019
  • 资助金额:
    $ 12.21万
  • 项目类别:
New Mexico Clinical Trials Node: Clinical research and practice to address substance use in diverse, rural and underserved populations
新墨西哥州临床试验节点:解决多样化、农村和服务不足人群的药物使用问题的临床研究和实践
  • 批准号:
    10379715
  • 财政年份:
    2019
  • 资助金额:
    $ 12.21万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了